News | Antiplatelet and Anticoagulation Therapies | May 25, 2016

Technavio Projects Top U.S. Anticoagulant Trends Through 2020

Company says new therapeutic uses, patient assistance programs and the decline of heparin’s market share will shape market through the rest of the decade

anticoagulants, U.S. market, Technavio, 2020, trends

May 25, 2016 — Technavio’s latest report on the U.S. anticoagulants market provides an analysis on the most important trends expected to impact the market outlook from 2016-2020. Technavio defines an emerging trend as a factor that has the potential to significantly impact the market and contribute to its growth or decline.

The top three emerging trends driving the anticoagulants market in the United States, according to Technavio healthcare and life sciences research analysts, are:

  • Expected exploitation of new therapeutic use;
  • Patient assistance programs; and
  • Declining shares of heparin market.

 

Expected exploitation of new therapeutic use

Heparin and related drugs are widely used for their anticoagulant activities. However, it has been identified that heparin exhibits anti-inflammatory activities and prevents the metastatic spread of tumor cells. Heparin exhibits anti-inflammatory activity by neutralizing cationic mediators, inhibiting adhesion molecules and heparanase, which are involved in leukocyte recruitment into tissues. Similarly, research studies indicate that heparin acts as an inhibitor of cell adhesion and elicits anti-metastatic activities. The drug is also found to target P- and L-selectin, and integrin activity, preventing cancer progression. Further studies are being conducted to exploit the use of heparin as an anti-inflammatory and antitumor agent. With frequent innovations there has been an increase in the development of heparin drugs as novel formulations and for the treatment of new indications.

“Ockham Biotech is developing inhaled heparin for the treatment of airway diseases, cystic fibrosis and asthma either alone or in combination with other drugs under various stages of development. Also the LMW Heparin MMX, which is under the Phase II stage of development by Cosmo Pharmaceuticals, is indicated for the treatment of ulcerative colitis,” said Barath Palada, a lead analyst at Technavio for cardiovascular and metabolic disorders research.

 

Patient assistance programs

Patient assistance programs for anticoagulants are expected to boost the growth of the market during the forecast period. The vendors in the market are providing co-pay assistance to patients who are purchasing the indicated medications for coagulation disorders. For instance, Daiichi Sankyo’s drug Savaysa has an assistance program to provide financial assistance to those consuming the drug. According to the support program, eligible patients are provided with a Savaysa Savings Card, which is available at $4 for a 30-day prescription and at $12 for a 90-day prescription. However, individuals who are enrolled for the Medicare/Medicaid program are not eligible for this savings program. Similarly, BMS provides assistance to patients buying its drugs through the Bristol-Myers Squibb Patient Assistance Foundation.

Only residents of the United States who are not insured under any other public or private insurance are eligible for assistance under this scheme. Apart from these, Janssen’s Xarelto CarePath Savings Card and Boehringer Ingelheim’s Pradaxa Savings Card allow eligible patients to acquire the drugs with minimum payment. “Since such assistance programs are provided by the drug suppliers, patients feel inclined toward purchasing branded therapies,” said Barath.

 

Declining shares of heparin market

The share of the heparin drugs market, which constitutes over half of the overall anticoagulants market, is declining at a significant rate owing to the availability of improved drugs in the market. This has reduced the overall heparin production, especially in developed countries because of shrinking demand from end-users. China remains the largest heparin active pharmaceutical ingredient (API) producer in the world and has a share of 80 percent of the global heparin API market. The market grew exponentially till 2009, and then experienced a decline due to the restrictions imposed after the 2008 adulterated heparin disaster, which led to the loss of hundreds of lives. This led to a decline in demand for heparin in Western countries and increased the regulatory standards for heparin API. However, the market has been experiencing slow growth in terms of the volume of heparin API being exported to other countries.

For more information: www.technavio.com

Related Content

The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in patients with pre-existing cardiovascular disease who were taking 81 milligrams (mg) baby aspirin, versus 325 mg of daily aspirin. Getty Images #ACC #ACC21 #ACC2021

The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in patients with pre-existing cardiovascular disease who were taking 81 milligrams (mg) baby aspirin, versus 325 mg of daily aspirin. Getty Images

News | Antiplatelet and Anticoagulation Therapies | May 15, 2021
May 15, 2021 — The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in pat
A Chinese registry study found there are higher event rates in patients with shorter dual-antiplatelet therapy (DAPT) after PCI procedures. There has been a lot of movement toward using shorter duration DAPT with newer generation drug-eluting stent technologies, but this study reinforces the need longer DAPT in many patients. The findings were presented as a late-breaking trial at SCAI 2021 today. 

A Chinese registry study found there are higher event rates in patients with shorter dual-antiplatelet therapy (DAPT) after PCI procedures. There has been a lot of movement toward using shorter duration DAPT with newer generation drug-eluting stent technologies, but this study reinforces the need longer DAPT in many patients. The findings were presented as a late-breaking trial at SCAI 2021 today. 

News | Antiplatelet and Anticoagulation Therapies | April 28, 2021
April 28, 2021 — An analysis of the prospective Chinese Fuwai PCI Registry, confirms long-term,...
Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can potentiate all 3 sides of Virchow’s Triad of coagulopathy, including endothelial dysfunction, blood flow stasis, and hypercoagulability. Angiotensin-converting enzyme-2 (ACE-2)–dependent viral entry and the virus-induced inflammatory response can lead to endothelial dysfunction. Clotting Prevention in COVID-19 Patients, Thrombosis Prevention in COVID-19 Patients, Preventing blood clots in COVID-19 patients

Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can potentiate all 3 sides of Virchow’s Triad of coagulopathy, including endothelial dysfunction, blood flow stasis and hypercoagulability. Angiotensin-converting enzyme-2 (ACE-2)–dependent viral entry and the virus-induced inflammatory response can lead to endothelial dysfunction. Additional figure included in the JACC article.

Feature | Antiplatelet and Anticoagulation Therapies | March 22, 2021 | By Dave Fornell, Editor
A comprehensive review or more than 80 randomized controlled trials (RCTs) investigating how to best manage optimal a
Tailor PCI trial showed genetic testing may play a role in personalizing antiplatelet therapy after PCI.
News | Antiplatelet and Anticoagulation Therapies | September 02, 2020
September 2, 2020 — An international, first-of-its-kind cardiology trial used personalized genetic testing to reduce
Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting. #ACC20 #ACC2020

Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting. 

News | Antiplatelet and Anticoagulation Therapies | March 28, 2020
March 28, 2020 — The TAILOR-PCI trial that used genetic testing to guide which antiplatelet medication was given to p